Accelerating the Translation of Cell Therapy for Type 1 Diabetes
ARMI CTO Dr. Tom Bollenbach will moderate manufacturing and AI sessions at an NIH workshop focused on advancing cell-replacement therapies for type 1 diabetes.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
